Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jianzhijia Pharmaceutical Chain Group Co., Ltd. (605266.SS)
Kunming, CN
Yunnan Jianzhijia Health-Chain Co., Ltd. operates a significant pharmaceutical retail enterprise throughout China. This company oversees an extensive chain of roughly 1,200 proprietary stores, complemented by its digital pharmacy platform. Shoppers can find a broad spectrum of items, encompassing household medications, vision care products like contact lenses and their solutions, various medical devices, sexual wellness goods, nutritional supplements, traditional Chinese herbal medicines, personal hygiene articles, infant products, and even ready-to-eat convenience foods. Established in Kunming, China, in 2004, the company maintains its headquarters there.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50% | -0.70% | +4.76% | -3.32% | -8.72% | +2.97% | -6.83% | -60.63% | -53.16% | -58.57% | -58.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-3.9% Q1'26: -8.9% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+20.5% ★ Q1'26: +9.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+7.4% Q1'26: +7.0% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+3.7% Q1'26: +3.0% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+3.3% Q1'26: +3.1% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%-4.0% ★ Q1'26: -2.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×4.61× Q1'26: 19.37× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.23B
est: 5.14B (+1.9%)
|
7.51B
est: 7.28B (+3.2%)
|
9.08B
est: 9.23B (-1.6%)
|
9.28B
est: 9.39B (-1.2%)
|
8.92B
est: 10.43B (-14.5%)
|
11.77B
11.77B – 11.77B
+12.8% YoY
|
| EBITDA |
439.04M
est: 720.19M (-39.0%)
|
602.74M
est: 1.02B (-41.0%)
|
723.98M
est: 662.86M (+9.2%)
|
384.20M
est: 674.77M (-43.1%)
|
1.14B
est: 749.12M (+52.4%)
|
845.23M
845.23M – 845.23M
+12.8% YoY
|
| EBIT |
408.03M
est: 323.27M (+26.2%)
|
549.85M
est: 458.27M (+20.0%)
|
656.22M
est: 600.97M (+9.2%)
|
315.16M
est: 611.78M (-48.5%)
|
327.88M
est: 679.18M (-51.7%)
|
766.32M
766.32M – 766.32M
+12.8% YoY
|
| Net Income |
300.53M
est: 315.13M (-4.6%)
|
374.29M
est: 331.50M (+12.9%)
|
414.41M
est: 321.75M (+28.8%)
|
128.13M
est: 175.98M (-27.2%)
|
148.15M
est: 262.43M (-43.5%)
|
314.91M
314.91M – 314.91M
+20.0% YoY
|
| SGA |
1.48B
est: 1.09B (+35.4%)
|
2.12B
est: 1.55B (+37.1%)
|
2.59B
est: 2.49B (+3.8%)
|
2.94B
est: 2.54B (+15.7%)
|
658.39M
est: 2.82B (-76.6%)
|
3.18B
3.18B – 3.18B
+12.8% YoY
|
| EPS |
2.15
est: 2.04 (+5.3%)
|
2.48
est: 2.15 (+15.5%)
|
2.69
est: 2.08 (+29.1%)
|
0.83
est: 1.14 (-27.2%)
|
1.00
est: 1.70 (-41.2%)
|
2.04
2.04 – 2.04
+20.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-05-06 | B+ | 3/5 | 5/5 | 3/5 | 3/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-29 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 3/5 | 4/5 | 1/5 | 2/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bo Lan | Chairman & GM | — | male |
| Fei Yang | Deputy General Manager | — | male |
| Heng Li | Chief Financial Officer, Deputy GM, Board Secretary & Director | — | male |
| Xuejin Song | Accounting Supervisor | — | — |
| Yanchun Shi | Deputy General Manager | — | female |
| Yanyin Jiang | Deputy General Manager | — | female |
| Yuming Hu | Deputy General Manager | — | male |
| Zhiqi Chai | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 605266.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
